Foundation for Sarcoidosis Research

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Prior to the launch of FSR's webinar on pulmonary sarcoidosis, Mary McGowan, CEO, discusses the private listening session held with the FDA that addressed the critical needs in the field.

New research has suggested that approximately 2%-5% of patients with sarcoidosis also struggle with cardiac sarcoidosis.

Sarcoidosis expert Dr. Wonder Drake got into the field after diagnosing a patient with the disease early in her career. In this interview she explains the best way to approach a suspected case of sarcoidosis.

In this interview, Dr. Wonder Drake shares physician resources and explains the unique presentation of sarcoidosis and how it varies by region.

With this new decade-long cohort, Dr. Chen notes that researchers are "one step closer to a more accurate view of what sarcoidosis may be like in the United States", with has been suggested to be more prominent in African American communities.

Sarcoidosis expert shares that one of her early patients had the rare disease and it was this young African American woman who inspired her to focus on treating the condition.

Dr. Obi speaks of the disparities associated with the disease, the challenges patients face, and how sarcoidosis – the “great mimicker” as some clinicians have described it- can be differentiated from other diseases.

Ennis James, MD, discusses the challenges and lingering questions associated with sarcoidosis